Troxerutin is an anticoagulant used in the treatment of hemorrhoids and venous disorders, including varicose veins, and in clinical trials for the treatment of chronic venous insufficiency. Troxerutin is a rutoside, a naturally occurring flavonoid. Troxerutin is a beneficial cofactor in coumarin preparations used for the therapy of chronic venous insufficiency due to its hepatoprotective properties. Locally administered troxerutin has anti-inflammatory action, which contributes to the rapid alleviation of symptoms related to venous inflammatory disease. Troxerutin is protective against gamma radiation-induced micronuclei formation and DNA strand breaks and enhances repair of radiation-induced DNA strand breaks.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Troxerutin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.